NASDAQ:GMDAGamida Cell Stock Price, Forecast & News

Gamida Cell's stock was trading at $4.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GMDA shares have increased by 14.9% and is now trading at $4.86. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Gamida Cell.

Gamida Cell is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Gamida Cell.

Gamida Cell Ltd (NASDAQ:GMDA) announced its quarterly earnings data on Thursday, May, 21st. The company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.12. View Gamida Cell's earnings history.

6 analysts have issued twelve-month price objectives for Gamida Cell's stock. Their forecasts range from $13.00 to $20.00. On average, they anticipate Gamida Cell's share price to reach $16.33 in the next year. This suggests a possible upside of 236.1% from the stock's current price. View analysts' price targets for Gamida Cell.

Media headlines about GMDA stock have been trending neutral recently, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Gamida Cell earned a news impact score of 0.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutGamida Cell.

Gamida Cell saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 32,900 shares, an increase of 5.8% from the April 30th total of 31,100 shares. Based on an average daily trading volume, of 28,500 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.3% of the shares of the company are sold short. View Gamida Cell's Current Options Chain.

Some companies that are related to Gamida Cell include Scholar Rock (SRRK), Voyager Therapeutics (VYGR), Harpoon Therapeutics (HARP), PDL BioPharma (PDLI), Precision BioSciences (DTIL), Verona Pharma (TARA), Tcr2 Therapeutics (TCRR), Eiger Biopharmaceuticals (EIGR), ADMA Biologics (ADMA), CASI Pharmaceuticals (CASI), Cellular Biomedicine Group (CBMG), Brainstorm Cell Therapeutics (BCLI), Gritstone Oncology (GRTS), Sutro Biopharma (STRO) and GENFIT S A/ADR (GNFT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), Aurora Cannabis (ACB), Aquestive Therapeutics (AQST), Outlook Therapeutics (OTLK), PhaseBio Pharmaceuticals (PHAS), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX) and Cyclacel Pharmaceuticals (CYCC).

(GMDA) raised $50 million in an initial public offering (IPO) on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

Gamida Cell's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alyeska Investment Group L.P. (0.88%).

GMDA stock was purchased by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P..

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GMDA stock can currently be purchased for approximately $4.86.

Gamida Cell has a market capitalization of $117.71 million. The company earns $-34,350,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Gamida Cell employs 79 workers across the globe.

The official website for Gamida Cell is www.gamida-cell.com.

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The company can be reached via phone at 972-2659-5666 or via email at [email protected]